This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Using index levels to time market involves aligning trades with key thresholds while avoiding over-interpretation of minor moves.
28,495 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Three durable businesses stand out for a buy-and-hold approach as markets adjust to AI-driven demand and steadier gro...
Two AI powerhouses clash in the investor spotlight. This guide breaks down how Alphabet and Meta are turning AI bets ...
A federal jury awarded $3 million to a woman in the first-ever social media addiction trial against Meta and Google, ...
A sharp look at how Rivian Automotive and Tesla earn money, where their revenue comes from, and what the trends mean ...
With whispers of funded shortfalls, retirees social security just may face tighter benefits. This guide breaks down w...
Two powerhouse ideas could propel your portfolio toward the next decade: a campus-wide AI infrastructure leader and a...
The Baupost founder made a bold, selective move: trim a large Alphabet stake and pivot to a fintech name that slumped...
Tesla just posted its strongest quarter in years, with a delivery beat powered by Model 3 and Model Y. This deep dive...
As custom AI chips gain traction, investors wonder if amazon alphabet's custom chips can rival Nvidia. This article b...
Rigetti Computing just reported a sharp revenue jump. This article breaks down what a tripling revenue figure could m...
A new wealth-building idea for families pitches a baby as a long-term investor. Experts warn that while the math can ...